HEPA Hepion Pharmaceuticals, Inc.

CIK 0001583771 50 ready 8-Ks latest October 9, 2026, 4:30 PM ET RSS · JSON

Activity: ELEVATED 3 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 50

Latest filing October 9, 2026, 4:30 PM ET

Top materiality 0.95

Event mix other_material ×26 · leadership ×14 · regulatory ×6

Sentiment 1 pos · 18 neg · 31 neu

Executive change recent →

SHENANIGAN SCORE 3 / 7 see the board

Recent 8-K filings for HEPA

Highest-materiality recent filing

Hepion Pharmaceuticals acquires Gravitas Life Sciences for $2M cash plus 25M shares and names new CEO and CFO

October 9, 2026, 4:30 PM ET M&A materiality 0.95 neutral item 1.01 item 2.01 item 9.01 item 3.02 item 5.02 ◈ executive_change ×2

Hepion acquired all Gravitas Life Sciences membership interests for $2,000,000 cash plus 25,000,000 shares (valued at $2,250,000) and an extra $135,000 payment.
The Purchase Agreement caps issuance at 19.99% of post-issuance outstanding shares, with any reduction settled in cash; shares have a six-month lock-up and piggyback registration rights.

Read filing →

October 9, 2026, 4:30 PM ET M&A materiality 0.95 neutral item 1.01 item 2.01 item 9.01 item 3.02 item 5.02 ◈ executive_change ×2

Hepion Pharmaceuticals acquires Gravitas Life Sciences for $2M cash plus 25M shares and names new CEO and CFO

Hepion acquired all Gravitas Life Sciences membership interests for $2,000,000 cash plus 25,000,000 shares (valued at $2,250,000) and an extra $135,000 payment.
October 2, 2026, 9:25 AM ET other material materiality 0.45 neutral item 5.03 item 9.01

Hepion raises authorized common stock to 750,000,000 shares via Delaware Certificate of Amendment

Certificate of Amendment filed with the Delaware Secretary of State and effective October 1, 2026, increased Hepion's authorized common stock to 750,000,000 shares.
September 28, 2026, 6:30 AM ET regulatory materiality 0.70 negative item 4.01 item 9.01

Hepion Pharmaceuticals replaces Grassi with RRBB as auditor amid going-concern doubt and material weaknesses

Hepion's audit committee approved dismissing Grassi & Co., CPAs, P.C. and engaging Rosenberg Rich Baker Berman P.A. as independent auditor on Sept. 21, 2026.
September 8, 2026, 5:24 PM ET debt materiality 0.40 neutral item 1.01 item 2.03 item 3.02 item 9.01

Hepion Pharmaceuticals issues $500K secured convertible note to Gravitas Capital

$500,000 secured convertible note with 8% paid-in-kind interest, maturing Sept 3, 2027.
August 27, 2026, 4:30 PM ET other material materiality 0.30 neutral item 1.01 item 3.02 item 9.01

Hepion raises $400K in private placement of 8M shares and warrants

Private placement of 8,000,000 common shares and 8,000,000 warrants at $0.05/share for gross proceeds of $400,000.
August 20, 2026, 4:45 PM ET leadership materiality 0.25 neutral item 5.02

Hepion Pharmaceuticals appoints James Liddy as director effective August 19, 2026

Board approved James Liddy as director on August 19, 2026, effective immediately.
August 4, 2026, 9:17 AM ET other material materiality 0.70 negative item 1.01 item 3.02 item 9.01

Hepion Pharmaceuticals raises $3.1M in private placement of 61.1M shares and warrants

Gross proceeds of $3,055,000 from sale of 61,100,000 shares at $0.05 per share.
July 2, 2026, 4:30 PM ET leadership materiality 0.30 neutral item 5.02

Hepion Pharmaceuticals appoints Danina Fisher and Gary S. Stetz, II to board

Danina Fisher and Gary S. Stetz, II appointed as directors effective July 1, 2026.
June 17, 2026, 4:15 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Hepion shareholders approve 40x increase in equity plan shares to 8M at annual meeting

Elected directors Stetz, V. LoPriore, Purcell, Appajosyula, C. LoPriore with ~13.5M votes each.
April 22, 2026, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 3.02 item 9.01 ◈ Equity Issuances◈ Material Agreements

Hepion Pharmaceuticals raises $700,000 in private placement of 17.5 million shares

Hepion entered securities purchase agreements with accredited investors on April 21, 2026, selling 17,500,000 shares at $0.04 per share.
April 14, 2026, 7:59 PM ET leadership materiality 0.55 neutral item 1.01 item 5.02

Hepion Pharma CEO Kaouthar Lbiati resigns; separation agreement provides $225K payment

Separation agreement pays Dr. Lbiati $225,000, $30,625 pro-rata bonus, and 6 months COBRA reimbursement.
March 18, 2026, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

Hepion Pharma CEO Kaouthar Lbiati resigns; Gary Stetz named interim CEO

CEO Dr. Kaouthar Lbiati resigned effective March 16, 2026, for personal reasons.
March 3, 2026, 6:59 PM ET other material materiality 0.50 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Hepion in-licenses ctRNA biomarker assay for early HCC detection from Cirna Diagnostics

Upfront $50K, milestones up to $2.35M, sales milestones up to $4.5M, low single-digit royalty.
January 15, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 5.02

Hepion Pharmaceuticals names Kaouthar Lbiati CEO effective Jan 8, 2026; salary $350K

Dr. Kaouthar Lbiati appointed CEO effective Jan 8, 2026, per Board approval on Jan 13, 2026.
June 30, 2025, 7:59 PM ET leadership materiality 0.65 negative item 5.02

Hepion Pharmaceuticals CFO John Brancaccio resigns; interim CFO named

John Brancaccio resigned as CFO and director effective June 30, 2025, for personal reasons.
June 12, 2025, 7:59 PM ET other material materiality 0.60 negative item 5.07

Hepion shareholders reject reverse stock split amendment at 2025 annual meeting

Reverse stock split proposal (1:5 to 1:20) failed with 2.25M for, 3.70M against; not approved.
June 9, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

Hepion appoints director Kaouthar Lbiati as interim CEO effective June 16

Dr. Kaouthar Lbiati, a board member since June 2022, appointed interim CEO effective June 16, 2025.
May 30, 2025, 7:59 PM ET other material materiality 0.80 negative item 1.01

Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones

Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.
May 12, 2025, 7:59 PM ET other material materiality 0.90 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices ×2

Hepion delisted from Nasdaq; pivots to diagnostics via New Day license

Received Nasdaq delisting notice for failing to maintain $1.00 bid price and being deemed a public shell; trading suspended May 13, 2025.
May 6, 2025, 7:59 PM ET M&A materiality 0.55 neutral item 1.01 item 3.02

Hepion in-licenses diagnostic tests from New Day Diagnostics for $0.725M upfront

In-licensed celiac, respiratory multiplex (COVID/flu A/B/RSV), H. pylori, and HCC tests; three have CE marks for EU sale.
April 17, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices

Nasdaq deems Hepion a 'public shell' as additional delisting basis; hearing April 29

Received Nasdaq notice on April 15, 2025, alleging company is a 'public shell' and continued listing unwarranted.
April 4, 2025, 7:59 PM ET other material materiality 0.55 neutral item 8.01 item 9.01

Hepion files amended balance sheet to correct warrant accounting; $6.14M warrant liability recorded

Amended 8-K/A filed to correct accounting for Series A and B warrants issued in Jan 2025 offering.
March 20, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 ◈ Listing & Compliance Notices

Hepion receives Nasdaq delisting notice as bid price falls below $0.10 for 10 days

Stock closed below $0.10 for 10 consecutive business days triggering the Low Priced Stocks Rule.
March 19, 2025, 7:59 PM ET other material materiality 0.50 neutral item 3.03 item 5.03 item 9.01 ◈ Governance Changes

Hepion Pharmaceuticals implements 1-for-50 reverse stock split effective March 17, 2025

Every 50 pre-split shares reclassified into 1 share; par value unchanged at $0.0001.
March 10, 2025, 7:59 PM ET other material materiality 0.65 neutral item 5.07

Hepion shareholders approve reverse stock split (1:10-1:50) at annual meeting

All four director nominees elected (Brancaccio, Block, Lbiati, Purcell) with majority 'For' votes.
March 4, 2025, 6:59 PM ET other material materiality 0.30 neutral item 8.01 item 9.01

Hepion Pharmaceuticals provides unaudited balance sheet as of Jan 31, 2025; cash of $5.36M

Cash and cash equivalents of $5.36M as of January 31, 2025.
January 15, 2025, 6:59 PM ET regulatory materiality 0.60 negative item 3.01 ◈ Listing & Compliance Notices ×2

Hepion Pharma receives Nasdaq delisting notice for failure to hold annual meeting; 45 days to submit compliance plan

Notice dated January 14, 2025 from Nasdaq for failing to hold annual shareholders' meeting within 12 months of fiscal year end.
December 11, 2024, 6:59 PM ET other material materiality 0.80 negative item 1.02 item 8.01 item 9.01

Hepion terminates merger with Pharma Two B; special meeting cancelled

Merger Agreement with Pharma Two B Ltd. terminated mutually on Dec 10, 2024.
November 21, 2024, 6:59 PM ET regulatory materiality 0.75 negative item 3.01

Hepion Pharma receives Nasdaq delisting notice due to stockholder deficit and failure to meet listing alternatives

Stockholders' deficit of ($406,685) as of Sept 30, 2024 triggers Nasdaq Listing Rule non-compliance.
September 5, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01

Hepion Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00

Notice received Sept. 3, 2024; bid price below $1.00 for 30 consecutive business days.
August 7, 2024, 7:59 PM ET leadership materiality 0.70 negative item 5.02 ◈ executive_change ×2

Hepion Pharma's interim CEO/CFO resigns; executive chairman takes over

John Cavan departed as interim CEO and CFO on August 5, 2024 for personal reasons.
July 22, 2024, 7:59 PM ET M&A materiality 0.80 neutral item 1.01 item 2.03 item 3.02 item 5.02 item 7.01 item 8.01 item 9.01

Hepion Pharmaceuticals enters definitive merger agreement with Pharma Two B Ltd., expects Q4 2024 close

Hepion will merge with Pharma Two B Ltd.; existing Hepion shareholders receive ordinary shares of Parent.
March 6, 2024, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Hepion appoints Michael Purcell to board as Audit Committee Chair

Michael Purcell appointed as director of Hepion Pharmaceuticals on March 5, 2024.
February 20, 2024, 6:59 PM ET leadership materiality 0.45 neutral item 5.02 ◈ executive_change ×2

Chairman Gary Jacob resigns from Hepion board; John Brancaccio appointed Chairman

Dr. Gary Jacob resigned as Chairman and from the Board on February 20, 2024, for personal reasons.
February 16, 2024, 6:59 PM ET other material materiality 0.60 negative item 1.01 item 3.02 item 9.01

Hepion raises $2.06M via warrant inducement, reduces exercise prices and issues new warrants

Holders of 980,393 Series B warrants will exercise at reduced price of $2.10/share, raising ~$2.06M gross proceeds.
February 7, 2024, 6:59 PM ET leadership materiality 0.55 negative item 5.02 ◈ executive_change

Hepion Pharma Director Anand Reddi resigns from board effective Feb 7, 2024

Anand Reddi resigned from Board of Directors on Feb 7, 2024.
January 3, 2024, 6:59 PM ET other material materiality 0.60 negative item 4.01 item 9.01 ◈ Auditor Changes ×2

Hepion Pharmaceuticals dismisses BDO, appoints Grassi as new auditor

BDO dismissed as independent auditor effective Jan 1, 2024; Grassi Advisors engaged to audit FY 2023 financials.
December 7, 2023, 6:59 PM ET leadership materiality 0.75 negative item 5.02 item 8.01 item 9.01 ◈ executive_change ×3

Hepion CEO resigns, interim CEO named; restructuring plan to cut costs 60%

Dr. Robert Foster resigns as CEO and director for personal reasons, effective immediately.
October 3, 2023, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 8.01 item 9.01 ◈ Material Agreements

Hepion Pharmaceuticals raises $5.0M in registered direct offering with warrants

Gross proceeds $5.0M from sale of 980,393 shares (or equivalents) at $5.10/share plus warrants.
September 6, 2023, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 ◈ executive_change ×2

Hepion CMO Todd Hobbs resigns; Stephen Harrison appointed Consultant Medical Director

Dr. Todd Hobbs resigned as CMO effective September 29, 2023; resignation not due to any disagreement with the Company.
July 24, 2023, 7:59 PM ET other material materiality 0.15 neutral item 7.01 item 9.01

Hepion provides corporate presentation; no material new financial or clinical data

Rencofilstat Phase 2b ASCEND-NASH enrolling; AI-POWR platform highlighted.
July 21, 2023, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 9.01 ◈ Material Agreements

Hepion Pharmaceuticals enters $24M ATM equity offering with Cantor Fitzgerald

ATM sales agreement with Cantor Fitzgerald allows Hepion to sell up to $24M of common stock at market prices.
June 22, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×4

Hepion Pharma stockholders elect all director nominees, ratify BDO, approve equity plan, pass say-on-pay

All seven director nominees elected; votes For ranged from 15.7M (Jacob) to 20.7M (Wijngaard).
May 22, 2023, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Hepion Phase 2 ALTITUDE-NASH trial meets primary endpoint with rencofilstat 225 mg improving liver function

Phase 2 trial met primary endpoint: 225 mg rencofilstat reduced DSI by 1.62 units (p<0.05) and SHUNT by 2.8% (p<0.05).
May 10, 2023, 7:59 PM ET other material materiality 0.55 neutral item 5.03 item 8.01 item 9.01 ◈ Governance Changes

Hepion Pharmaceuticals effects 1-for-20 reverse stock split to regain Nasdaq compliance

Reverse split ratio 1-for-20 effective 4:01pm ET May 10, 2023; split-adjusted trading begins May 11 under same symbol HEPA.
December 16, 2022, 6:59 PM ET other material materiality 0.50 neutral item 5.07 ◈ Shareholder Votes

Hepion shareholders approve reverse stock split; Board to set ratio 1:2 to 1:20

Special meeting held Dec 15, 2022; proposal to amend charter for reverse split approved.
November 9, 2022, 6:59 PM ET other material materiality 0.80 neutral item 1.01 item 3.02 item 3.03 item 5.03 item 8.01 item 9.01 ◈ Material Agreements

Hepion Pharmaceuticals Raises $20M via Private Placement of Convertible Preferred Stock

Offering includes 1,900,000 Series F and 100,000 Series G shares at $9.50 each.
October 17, 2022, 7:59 PM ET other material materiality 0.50 neutral item 7.01 item 9.01

Hepion reports $71.7M cash; progressing Phase 2 NASH and upcoming HCC trials

Cash and equivalents of $71.7M as of June 30, 2022; 76.2M common shares outstanding.
August 5, 2022, 7:59 PM ET other material materiality 0.15 negative item 5.07

Hepion shareholders reject authorized share increase from 120M to 200M

Proposal received 19,267,720 For, 27,847,827 Against, 254,176 Abstain; broker non-votes 1.
June 28, 2022, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 item 9.01 ◈ executive_change ×2

Hepion appoints Anand Reddi and Kaouthar Lbiati to Board of Directors

Board expanded to 8; Reddi and Lbiati appointed independent directors effective June 27, 2022.